Hormone Therapy Flashcards
Prednisone (Meticorten) Class
Glucocorticoids
Prednisone (Meticorten) Mechanism
Inhibit mitosis in lymphocytes
Prednisone (Meticorten) Therapeutics
ALL; combination for Hodgkin’s, non-Hodkin’s, multiple myeloma, and CLL
Dexamethasone (Decadron) Class
Glucocorticoids
Dexamethasone (Decadron) Mechanism
Inhibit mitosis in lymphocytes
Dexamethasone (Decadron) Therapeutics
Reduces edema in brain and spinal cord tumors with radiation therapy
Tamoxifen (Soltamox) Class
Selective estrogen-receptor modulators(SERMs)
Tamoxifen (Soltamox) Mechanism
Competes with estradiol for binding to estrogen receptor
Tamoxifen (Soltamox) Therapeutics
ER-positive breast cancer, or as adjuvant therapy following primary breast tumor excision; prevention of breast cancer in high-risk patients
Tamoxifen (Soltamox) Important side effects
Hot flushes, hair loss; increased risk of endometrial cancer;increased risk of thromboembolic events
Tamoxifen (Soltamox) Other side effects
Nausea and vomiting
Fulvestrant (Faslodex) Class
Selective estrogen-receptor downregulators(SERDs)
Fulvestrant (Faslodex) Mechanism
Binds with much higher affinity (>100-fold)to estrogen receptor than tamoxifen,inhibiting dimerization, increasing degradation, and reducing overall ER levels
Fulvestrant (Faslodex) Therapeutics
Posmenopausal women with ER positive metastatic breast cancer
Aminoglutethamide (Cytadren) Class
Aromatase inhibitors
Aminoglutethamide (Cytadren) Mechanism
Inhibits function of aromatase
Aminoglutethamide (Cytadren) Therapeutics
Relatively weak, used against breastcancer
Anastrozole (Arimidex) Class
Aromatase inhibitors
Anastrozole (Arimidex) Mechanism
Inhibits function of aromatase
Anastrozole (Arimidex) Therapeutics
First-line for ER-positive breast cancer in postmenopausal women
Letrozole (Femara) class
Aromatase inhibitors
Letrozole (Femara) Mechanism
Inhibits function of aromatase
Letrozole (Femara) Therapeutics
ER-positive breast cancer in postmenopausal women
Exemestane (Aromasin) class
Aromatase inhibitors
